Cullinan Therapeutics NDA for zipalertinib in advanced NSCLC accepted by FDA

Cullinan Therapeutics NDA for zipalertinib in advanced NSCLC accepted by FDA
Cullinan NDA for zipalertinib cleared

Cullinan Therapeutics, in partnership with Taiho Oncology and Taiho Pharmaceutical, announced that the U.S. Food and Drug Administration has accepted its New Drug Application for zipalertinib, targeting locally advanced or metastatic EGFR exon 20 insertion non-small cell lung cancer following platinum-based chemotherapy.

This regulatory milestone marks significant progress in the development of zipalertinib, reinforcing the collaboration’s commitment to expanding treatment options for patients with difficult-to-treat forms of lung cancer. Additional details about the review timeline and potential market launch have not yet been provided.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.